Skip to main content
. 2022 Dec 16;10(1):118–129. doi: 10.1002/acn3.51708

Figure 3.

Figure 3

sGFAP levels in ALS patients with and without eye movement abnormalities. Horizontal bars represent median values. ALS, amyotrophic lateral sclerosis; EMA+, patients with eye movement abnormalities; EMA−, patients without eye movement abnormalities. sGFAP, serum glial fibrillary acidic protein.